[go: up one dir, main page]

ES2119996T3 - Composicion inyectable que comprende faclitaxel. - Google Patents

Composicion inyectable que comprende faclitaxel.

Info

Publication number
ES2119996T3
ES2119996T3 ES94901593T ES94901593T ES2119996T3 ES 2119996 T3 ES2119996 T3 ES 2119996T3 ES 94901593 T ES94901593 T ES 94901593T ES 94901593 T ES94901593 T ES 94901593T ES 2119996 T3 ES2119996 T3 ES 2119996T3
Authority
ES
Spain
Prior art keywords
taxol
solution
faclitaxel
composition including
injectable composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94901593T
Other languages
English (en)
Inventor
David R Carver
Timothy R Prout
Hernita Ewald
Robyn Elliott
Paul Handreck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tapestry Pharmaceuticals Inc
Original Assignee
Tapestry Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25644377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2119996(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tapestry Pharmaceuticals Inc filed Critical Tapestry Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2119996T3 publication Critical patent/ES2119996T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICION DE TAXOL Y ACEITE DE RICINO POLIETOXILADO CUYO PH SE COMPENSA PARA OBTENER UN PH INFERIOR A 8.1 QUE MEJORE LA ESTABILIDAD. ESTA COMPOSICION PUEDE INCLUIR UN ACIDO, PREFERENTEMENTE ACIDO CITRICO, PARA RECTIFICAR EL VALOR DEL PH. EL DESCUBRIMIENTO INCLUYE UN METODO DE FORMULACION DE UNA SOLUCION DE TAXOL INYECTABLE, MEZCLANDO UN ACIDO CON UNA SUBSTANCIA PORTADORA, COMO EL ACEITE DE RICINO, PARA OBTENER UNA SOLUCION PORTADORA TRAS LO CUAL SE MEZCLA EL TAXOL CON LA SOLUCION PORTADORA PARA OBTENER LA SOLUCION DE TAXOL CON PH INFERIOR A 8.1. EL METODO PUEDE INCLUIR UNA FASE DE SUSPENSION DEL TAXOL EN ALCOHOL ANTES DE MEZCLARLO CON LA SOLUCION PORTADORA.
ES94901593T 1992-11-27 1993-11-18 Composicion inyectable que comprende faclitaxel. Expired - Lifetime ES2119996T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL607492 1992-11-27
US99550192A 1992-12-22 1992-12-22

Publications (1)

Publication Number Publication Date
ES2119996T3 true ES2119996T3 (es) 1998-10-16

Family

ID=25644377

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94901593T Expired - Lifetime ES2119996T3 (es) 1992-11-27 1993-11-18 Composicion inyectable que comprende faclitaxel.
ES97121710T Expired - Lifetime ES2224200T3 (es) 1992-11-27 1993-11-18 Composicion inyectable estable de paclitaxel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES97121710T Expired - Lifetime ES2224200T3 (es) 1992-11-27 1993-11-18 Composicion inyectable estable de paclitaxel.

Country Status (12)

Country Link
US (7) US5733888A (es)
EP (4) EP0674510B1 (es)
JP (1) JP2880292B2 (es)
AT (2) ATE169216T1 (es)
AU (1) AU5612694A (es)
CA (2) CA2149150C (es)
DE (2) DE69320206T2 (es)
DK (2) DK0835657T3 (es)
ES (2) ES2119996T3 (es)
GR (1) GR3027724T3 (es)
PT (1) PT835657E (es)
WO (2) WO1994012030A1 (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2119996T3 (es) * 1992-11-27 1998-10-16 Napro Biotherapeutics Inc Composicion inyectable que comprende faclitaxel.
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
FR2710534B1 (fr) * 1994-09-28 1996-07-05 Bristol Myers Squibb Co Solvant de stabilisation, composition pharmaceutique le contenant, et son procédé de préparation.
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
DE19536165A1 (de) * 1995-09-28 1997-04-03 Basf Ag Verfahren zur Reinigung von alkoxylierten Fetten
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CN1209059A (zh) * 1995-12-21 1999-02-24 基因实验室技术有限公司 紫杉烷类组合物及方法
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
AU741439B2 (en) 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
CA2347097C (en) 1998-10-20 2009-06-16 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
CN1361760A (zh) 1999-05-14 2002-07-31 尼瑞斯药品公司 新的白介素－1和肿瘤坏死因子－α调节剂、所述调节剂的合成以及使用所述调节剂的方法
DE19925211B4 (de) * 1999-06-01 2006-01-12 PBS Pharmaceutical Bulk Substances SA Kit zur Herstellung einer Formulierung von Paclitaxel
JP2003520230A (ja) * 2000-01-20 2003-07-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 活性炭を用いたポリオキシエチル化ヒマシ油の精製およびこれの医薬組成物
JP2003521545A (ja) * 2000-02-02 2003-07-15 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 改良された溶解性を有するタキサン製剤
DE60139544D1 (de) * 2000-02-23 2009-09-24 Life Technologies Corp Veränderte, fluoreszierende proteine
US6951885B2 (en) 2000-08-10 2005-10-04 Takeda Pharmaceutical Company Limited Pharmaceutical composition
JP4922507B2 (ja) * 2000-08-10 2012-04-25 武田薬品工業株式会社 医薬組成物
EP1341414B1 (en) * 2000-11-16 2013-01-02 The Regents of The University of California Marine actinomycete taxon for drug and fermentation product discovery
US6919370B2 (en) 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US7141251B2 (en) 2001-04-06 2006-11-28 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
CA2466851C (en) * 2001-11-26 2012-09-11 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
KR20040066921A (ko) * 2001-12-20 2004-07-27 브리스톨-마이어스스퀴브컴파니 생체이용률이 향상된 경구 활성 탁산 유도체의 제약조성물
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
DK2286795T3 (en) 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
ES2295695T3 (es) * 2002-08-02 2008-04-16 Nereus Pharmaceuticals, Inc. Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7112581B2 (en) * 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
US20040122081A1 (en) * 2002-11-08 2004-06-24 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
EP1606065A4 (en) * 2003-02-11 2010-09-29 Univ Northwestern METHOD AND MATERIALS FOR NANOCRYSTALLINE SURFACE COATINGS AND ATTACHMENT OF AMPHIPHILENE PEPTIDE NANO FIBERS THEREOF
US20050049294A1 (en) * 2003-06-20 2005-03-03 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
CN101791306A (zh) * 2003-06-20 2010-08-04 加利福尼亚大学董事会 盐孢菌酰胺及其使用方法
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
PT1694660E (pt) * 2003-12-12 2009-07-16 Quiral Quimica Do Brasil Processo de preparação de ingredientes farmacêuticos activos (api) anidros e hidratados; composições farmacêuticas estáveis preparadas a partir dos mesmos e utilizações das referidas composições
WO2005070922A2 (en) * 2004-01-23 2005-08-04 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobials agents
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
JP2007535559A (ja) * 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びその使用法
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
WO2006060676A1 (en) 2004-12-03 2006-06-08 Dana Farber Cancer Institute Compositions and methods for treating neoplastic diseases
KR20060121721A (ko) * 2005-05-23 2006-11-29 주식회사 중외제약 테트라플루오로벤질 유도체 또는 그의 염을 함유하는주사제용 조성물
WO2006133510A1 (en) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
US7893299B2 (en) 2005-07-21 2011-02-22 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-αmodulators; syntheses of such modulators and methods of using such modulators
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
ES2784794T3 (es) * 2005-08-31 2020-10-01 Abraxis Bioscience Llc Composiciones que comprenden agentes farmacéuticos poco solubles en agua y agentes antimicrobianos
CN100548274C (zh) * 2006-01-12 2009-10-14 永信药品工业股份有限公司 紫杉醇水性注射液及其制备方法
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
FR2912745A1 (fr) * 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
BRPI0912234A2 (pt) * 2008-05-12 2015-10-06 Nereus Pharmaceuticals Inc derivados de salinosporamida como inibidores de proteassomas
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) * 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
MX342324B (es) 2011-03-29 2016-09-23 Sanofi Sa Formulaciones de otamixaban con estabilidad mejorada.
US20140234345A1 (en) * 2011-07-11 2014-08-21 Biolyse Pharma Corporation Novel anti-cancer isocarbostyril alkaloid conjugates
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2968390A4 (en) * 2013-03-15 2016-10-26 Epizyme Inc INJECTABLE FORMULATIONS FOR THE TREATMENT OF CANCER
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
JP2017527614A (ja) 2014-09-02 2017-09-21 ブピンダー シン 重水素化又は非重水素化分子及び医薬製剤
JP2017527567A (ja) * 2014-09-17 2017-09-21 エピザイム インコーポレイテッド 癌の治療のための注射製剤
CA2963923A1 (en) 2014-10-08 2016-04-14 Pacific Northwest Research Institute Methods and compounds for increasing the potency of antifungal agents
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
MY194341A (en) 2015-03-06 2022-11-29 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
US10561766B2 (en) 2015-09-15 2020-02-18 W. L. Gore & Associates, Inc. Drug composition and coating
IL260933B2 (en) 2016-02-08 2023-04-01 Beyondspring Pharmaceuticals Inc Preparations containing tocorsol or its analogues
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
KR20190015361A (ko) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
WO2018144764A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
MX2020010036A (es) 2018-03-28 2021-03-02 Herbalife Int Of America Inc Acetilacion de polisacaridos.
US11439586B2 (en) * 2018-10-16 2022-09-13 US Nano Food & Drug INC Intratumour injection formulation
EP4135686A4 (en) 2020-04-13 2025-03-12 US Nano Food & Drug Inc BASIC CHEMOTHERAPEUTIC INTRATUMORAL INJECTION FORMULATION
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
WO2024173418A1 (en) 2023-02-16 2024-08-22 Infinitum Health, Llc Methods of inhibiting cancer growth and inhibiting viral infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS552421B2 (es) * 1971-08-06 1980-01-19
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
EP0468044B1 (en) * 1990-02-15 1995-10-11 PQ Corporation Method of frying oil treatment using an alumina and amorphous silica composition
TW223634B (es) * 1991-03-18 1994-05-11 Kingston David G I
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
KR100371062B1 (ko) * 1992-11-27 2003-04-21 에프.에이치.포울딩 앤드 컴퍼니 리미티드 안정성이향상된주사가능한택솔조성물및이를제형화하는방법
ES2119996T3 (es) * 1992-11-27 1998-10-16 Napro Biotherapeutics Inc Composicion inyectable que comprende faclitaxel.
US5281727A (en) * 1992-11-27 1994-01-25 Napro Biotherapeutics, Inc. Method of using ion exchange media to increase taxane yields
HU213200B (en) 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5733388A (en) 1994-08-11 1998-03-31 Daido Tokiushuko Kabushiki Kaisha Steel composition for bearings and method of producing the same

Also Published As

Publication number Publication date
CA2308082A1 (en) 1994-06-09
JP2880292B2 (ja) 1999-04-05
DE69333605T2 (de) 2005-02-03
CA2149150A1 (en) 1994-06-09
CA2149150C (en) 2000-08-01
EP0674510A1 (en) 1995-10-04
DE69320206T2 (de) 1999-02-11
ES2224200T3 (es) 2005-03-01
DE69320206D1 (de) 1998-09-10
US20040204479A1 (en) 2004-10-14
US6306894B1 (en) 2001-10-23
US5972992A (en) 1999-10-26
ATE169216T1 (de) 1998-08-15
DE69333605D1 (de) 2004-09-30
EP0835657A1 (en) 1998-04-15
US6140359A (en) 2000-10-31
PT835657E (pt) 2004-11-30
EP0835657B1 (en) 2004-08-25
EP1500393A1 (en) 2005-01-26
DK0674510T3 (da) 1999-05-10
US5733888A (en) 1998-03-31
US20030065022A1 (en) 2003-04-03
EP0674510A4 (en) 1995-08-12
GR3027724T3 (en) 1998-11-30
EP1384474A1 (en) 2004-01-28
AU5612694A (en) 1994-06-22
EP0674510B1 (en) 1998-08-05
WO1994012030A1 (en) 1994-06-09
US6770670B2 (en) 2004-08-03
JPH08503945A (ja) 1996-04-30
DK0835657T3 (da) 2005-01-10
ATE274347T1 (de) 2004-09-15
WO1994012031A1 (en) 1994-06-09
US5977164A (en) 1999-11-02

Similar Documents

Publication Publication Date Title
ES2119996T3 (es) Composicion inyectable que comprende faclitaxel.
ATE201328T1 (de) Hochkonzentriertes immunglobulin-präparat und verfahren zu seiner herstellung
ATE68704T1 (de) Gegenueber lichteinfluss stabilisiertes nifedipin- konzentrat und verfahren zu seiner herstellung.
ZA924926B (en) Cosmetic composition
NO307206B1 (no) Preparater på basis av virkestoffer fra taxanklassen samt perfusjonspreparat inneholdende disse
ATE98473T1 (de) Orale praeparate gegen zahnbelaege.
DE68908730D1 (de) Synergistische biozide Zusammensetzung.
ATE96678T1 (de) Verfahren zur verminderung von hautirritationen bei anwendung von durchdringungsverstaerkenden arzneimittelzusammensetzungen.
ATE82139T1 (de) Eine lipidloesliche substanz enthaltende waessrige fluessigkeit.
PT91602A (pt) Processo para a preparacao de compostos espiro com accao antibacteriana e de composicoes farmaceuticas que os contem
KR870000072A (ko) 아졸 유도체를 함유하는 제제물 및 외상없이 손톱을 제거하기 위한 그 용도
ATE225340T1 (de) Einschlusskomplexe von taxol oder taxotere oder taxus-extrakten und cyclodextrinen, ihre herstellung und ihre verwendung
ES2068725T3 (es) Preparacion estable que contiene hidrocloruro de azelastina.
ATE159713T1 (de) N-acylglutamin-derivate
ES2084328T3 (es) Mezcla de estabilizador.
HUT66153A (en) Pharmaceutical compositions which can be used for preventing and treating of chemotherapy-induced alopecia
PL289266A1 (en) Method of stabilizing 3-isothiazolones and compositions containing them
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
ATE82850T1 (de) Verwendung von 2-pyrimidinyl-1-piperazinderivaten.
SE8503447L (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
KR890001568A (ko) 돼지 이질의 예방 및 치료제
DE3682380D1 (de) Stabilisiertes gossyplure und verfahren zu dessen herstellung.
KR890014001A (ko) 미세조류증식용 조성물
KR860003012A (ko) (-)시스-1,2-에폭시프로필포스폰산과 아미노산과의 염을 함유하는 수용성 제약 조성물
UA10906C2 (uk) Препарат для профілактики і лікуваhhя авітаміhозів сільськогосподарських твариh та птиці

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 674510

Country of ref document: ES